AXNX vs. CMD, NUVA, ATRC, SILK, CSII, PODD, SWAV, SOLV, TFX, and GMED
Should you be buying Axonics stock or one of its competitors? The main competitors of Axonics include Cantel Medical (CMD), NuVasive (NUVA), AtriCure (ATRC), Silk Road Medical (SILK), Cardiovascular Systems (CSII), Insulet (PODD), Shockwave Medical (SWAV), Solventum (SOLV), Teleflex (TFX), and Globus Medical (GMED). These companies are all part of the "medical" sector.
Axonics (NASDAQ:AXNX) and Cantel Medical (NYSE:CMD) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Axonics presently has a consensus price target of $70.30, indicating a potential upside of 4.78%. Given Axonics' higher probable upside, equities research analysts plainly believe Axonics is more favorable than Cantel Medical.
In the previous week, Axonics had 5 more articles in the media than Cantel Medical. MarketBeat recorded 5 mentions for Axonics and 0 mentions for Cantel Medical. Axonics' average media sentiment score of 1.06 beat Cantel Medical's score of 0.00 indicating that Axonics is being referred to more favorably in the media.
Cantel Medical has a net margin of 4.72% compared to Axonics' net margin of -4.12%. Cantel Medical's return on equity of 12.13% beat Axonics' return on equity.
99.5% of Axonics shares are held by institutional investors. Comparatively, 84.1% of Cantel Medical shares are held by institutional investors. 1.9% of Axonics shares are held by insiders. Comparatively, 10.7% of Cantel Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cantel Medical has higher revenue and earnings than Axonics. Axonics is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.
Cantel Medical received 37 more outperform votes than Axonics when rated by MarketBeat users. However, 66.92% of users gave Axonics an outperform vote while only 65.53% of users gave Cantel Medical an outperform vote.
Axonics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
Summary
Cantel Medical beats Axonics on 10 of the 17 factors compared between the two stocks.
Get Axonics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
